Peripheral Neuropathic Articles & Analysis
28 news found
XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report that it has filed a patent application for a significant library of novel psychedelic compounds. Each compound was designed to provide specific alterations in their respective biopharmaceutical properties. The library of compounds can be selected to target ...
PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022 DAEJEON, South Korea, October 17, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the Company will present preclinical data of PMC-309, one of the Company’s first immuno-oncology ...
Clinical data demonstrating initial safety and efficacy from the RESKUE trial are being presented by Chief Medical Officer Maria Escolar, M.D., at the 29th Congress of European Society of Gene & Cell Therapy (ESGCT), October 11-14, 2022 Subjects treated with FBX-101 have shown increased galactocerebrosidase (GALC) enzyme activity in plasma and cerebrospinal fluid (CSF), normal white matter ...
VisionQuest Biomedical founder and CEO Peter Soliz (PhD) has just been awarded a $1 million Commercialization Readiness Pilot Program (CRP) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (part of the US National Institutes of Health) for his work on early detection of DPN. With the support of this grant, Dr. Soliz will develop a commercial prototype and seek FDA ...
– AMVUTTRA Demonstrated Halting or Reversal in Neuropathy Impairment with Subcutaneous Administration Once Every Three Months – – Decision Follows Positive Opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) in July 2022 – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 20, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), ...
FBX-101 clinical data demonstrating safety and initial efficacy from the RESKUE trial is being presented at the 2022 Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium FBX-101 is a systemic AAV gene therapy following unrelated cord blood transplantation (“UCBT”) and has been well tolerated through Day 180 FBX-101 significantly increased GALC enzyme ...
VisionQuest founder and CEO Peter Soliz (PhD) presented the poster “Detecting diabetic peripheral neuropathy utilizing thermoregulation biomarkers of the plantar foot” at the American Diabetes Association’s 82nd Scientific Sessions last Sunday in New Orleans. “I was so glad to be able to meet with colleagues and make new connections in person after not traveling for over ...
When NIH scientists reviewed our grant application for the use of KLS-13019 in chemotherapy induced neuropathic pain (CIPN), we received an exceptional score of 20. This speaks volumes to the science behind the score. ...
How much do you know about the development of your favorite products? What about the devices you encounter at your doctor’s office? So much of the work that goes into every single thing we use remains unseen by the user or consumer, from concept development to design to ...
Published Preclinical Data Shows KLS-13019 More Effective Than Cannabidiol (CBD) in Prevention, Reversal of Chemotherapy-Induced Peripheral Neuropathy (CIPN) DOYLESTOWN, PA – April 13, 2022 – Neuropathix, Inc. ...
About KLS-13019 KLS-13019 is Neuropathix patented lead clinical compound for the potential treatment of a range of inflammatory, neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 is a monotherapeutic non-opioid cannabinoid derivative that has been shown to prevent and reverse ...
We have submitted our third Commercialization Readiness Pilot (CRP) Program grant application to the National Institutes of Health (NIH). In it, we describe our plan to commercialize i-RxTherm, our device for early diabetic peripheral neuropathy detection and diagnosis. ...
We’re looking forward to presenting “Detecting Diabetic Peripheral Neuropathy Utilizing Thermoregulation of the Plantar Foot” at the upcoming 82nd Scientific Sessions of the American Diabetes Association. Our research aims to detect thermal (infrared) biomarkers of diabetic peripheral neuropathy on the feet of diabetic subjects who have not been diagnosed with DPN. By analyzing ...
REDWOOD CITY, Calif., Jan. 25, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today responded to Medtronic's announcement of FDA approval for painful diabetic neuropathy (PDN). "PDN represents a very large potential market, and having another competitor validate this large ...
About KLS-13019 KLS-13019 is Neuropathix patented lead clinical target for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). ...
(“Neuropathix” or the “Company”) (OTCQB:NPTX), a socially responsible life sciences company focused on the research and development of a non-opioid platform of therapeutics to treat chronic and acute inflammation, and neuropathic pain, announced today that it has chosen to engage Purisys LLC to optimize and scale up KLS-13019 as the Company moves forward ...
Adding to the equation is the off-label use of opioids and gabapentinoids for chronic and neuropathic pain as a result of the unmet medical need and no FDA approved non-opioid drug to treat chronic and neuropathic pain, specifically Chemotherapy-induced peripheral neuropathy (CIPN). ...
Over the past ten years, Neuropathix has discovered, developed, and patented a global intellectual property estate, led by its lead clinical target, KLS-13019, as novel, new therapeutic agents designed to prevent and reverse neuropathic pain, reduce oxidative stress, and act as anti-inflammatory neuroprotectants. ...
Over the past ten years, Neuropathix has discovered, developed, and patented a global intellectual property estate, led by its lead clinical target, KLS-13019, as novel, new therapeutic agents designed to prevent and reverse neuropathic pain, reduce oxidative stress, and act as anti-inflammatory neuroprotectants. ...
Baron’s research focuses on exploring the mechanisms behind the formation of nerve pain, as well as the treatment of neuropathic pain syndromes. He was involved in developing a mechanism-related phenotyping strategy for neuropathic pain patients. ...